Literature DB >> 17531924

Beta2-adrenergic receptor gene polymorphisms and risk of ischemic stroke.

Rosita Stanzione1, Emanuele Di Angelantonio, Anna Evangelista, Daniela Barbato, Simona Marchitti, Bastianina Zanda, Angelo Pirisi, Giovanni Quarta, Massimo Volpe, Speranza Rubattu.   

Abstract

BACKGROUND: Beta2-adrenergic receptors (beta2-AR) mediate vasorelaxation in response to adrenergic agents. Genetic polymorphisms of beta2-AR were implicated in various cardiovascular and noncardiovascular traits.
METHODS: We tested the role of the beta2AR-16 and beta2AR-27 gene variants in the susceptibility to the development of ischemic stroke in a genetically homogenous and clinically well-characterized case-control sample that included 294 cases and 286 controls from Sardinia, Italy. This population was shown to be an optimal study sample for carrying out genetic analyses.
RESULTS: Age, hypertension, dyslipidemia, and atrial fibrillation were independent risk factors for stroke in this cohort. We found that the presence of the Glu27 allelic variant was associated with a significantly increased risk of stroke when assuming a recessive mode of inheritance (odds ratio [OR], 1.68; 95% confidence interval [CI], 1.17-2.41; P = .005). The same results were obtained for the subgroup of ischemic strokes of arterial origin (n = 215): OR, 1.71; 95% CI, 1.14-2.57; P = .009. Furthermore, haplotype analysis confirmed that the presence of the Glu27 allele increased the risk of cerebrovascular accidents.
CONCLUSIONS: Our data suggest that the Glu27 allelic variant of the beta2-AR gene may be a determinant of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531924     DOI: 10.1016/j.amjhyper.2007.01.006

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

1.  Role of Uncoupling Protein 2 Gene Polymorphisms on the Risk of Ischemic Stroke in a Sardinian Population.

Authors:  Rosita Stanzione; Maria Cotugno; Maurizio Forte; Franca Bianchi; Simona Marchitti; Nicole Piera Palomba; Teresa Esposito; Bastianina Zanda; Alessandra Sanna; Speranza Rubattu
Journal:  Life (Basel)       Date:  2022-05-12

2.  Genetics of adrenergic signaling drives coronary artery calcification.

Authors:  Jessica Gambardella; Xujun Wang; Pasquale Mone; Wafiq Khondkar; Gaetano Santulli
Journal:  Atherosclerosis       Date:  2020-08-17       Impact factor: 5.162

3.  Association of beta-1 and beta-2 adrenergic receptor gene polymorphisms with myocardial infarction.

Authors:  Akin Yilmaz; Mehmet G Kaya; Ulgen Merdanoglu; Mehmet A Ergun; Atiye Cengel; Sevda Menevse
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

4.  Association between polymorphisms in the beta2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women.

Authors:  Markus Schürks; Tobias Kurth; Paul M Ridker; Julie E Buring; Robert Y L Zee
Journal:  Thromb Haemost       Date:  2009-02       Impact factor: 5.249

Review 5.  Association between Beta Adrenergic Receptor Polymorphism and Ischemic Stroke: A Meta-Analysis.

Authors:  Amit Kumar; Manya Prasad; Pradeep Kumar; Arun Kumar Yadav; Awadh Kishor Pandit; Prachi Kathuria
Journal:  J Stroke       Date:  2015-05-29       Impact factor: 6.967

6.  Gln27Glu variant of Beta2-adrenoceptor gene affects male type fat accumulation in women.

Authors:  Tarja Kunnas; Riikka Lahtio; Marja-Leena Kortelainen; Anne Kalela; Seppo T Nikkari
Journal:  Lipids Health Dis       Date:  2009-10-15       Impact factor: 3.876

7.  Relationship between polymorphisms in beta -2 adrenergic receptor gene and ischemic stroke in North Indian Population: a hospital based case control study.

Authors:  Amit Kumar; Manjari Tripathi; Madakasira Vasantha Padma Srivastava; Subbiah Vivekanandhan; Kameshwar Prasad
Journal:  BMC Res Notes       Date:  2014-06-25

Review 8.  Ischemic Stroke and Sleep: The Linking Genetic Factors.

Authors:  Lyudmila Korostovtseva
Journal:  Cardiol Ther       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.